3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivatives, and preparation method and application thereof
By developing 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivatives as TLR2/1 agonists, the high cost and safety issues of existing anti-radiation drugs have been resolved, achieving highly efficient and low-toxicity anti-radiation and anti-tumor effects.
Patent Information
- Application Number
- CN202311148921.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-07
- Publication Date
- 2025-12-26
- Estimated Expiration
- 2043-09-07
AI Technical Summary
Existing anti-radiation drugs such as Leukine, Neupogen, and Neulasta have problems such as high production and storage costs, poor compliance with injection administration, and the potential to cause harmful immune reactions. Furthermore, there is currently a lack of effective drugs for the treatment of neurovascular acute radiation syndrome.
A class of 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivatives were developed as TLR2/1 agonists, providing anti-radiation and anti-tumor effects by activating the expression of relevant anti-radiation cytokines in vivo.
This compound is highly efficient and low in toxicity, effectively preventing and treating ionizing radiation damage, and exhibiting inhibitory effects on various cancer cells, providing a new direction for anti-radiation and anti-tumor drugs.
Smart Images

Figure CN117186082B_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application belongs to the field of medicine, and particularly relates to 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivatives and a preparation method thereof, and use thereof as anti-radiation drugs and anti-tumor drugs. BACKGROUND
[0002] With the wide application of nuclear technology, the risk of nuclear radiation damage to people cannot be ruled out. When the whole body or part of the human body is exposed to radiation greater than 1 Gy, acute radiation syndrome (ARS) will be induced. According to the size of the exposure dose and the clinical damage characteristics, it can be divided into: hematopoietic acute radiation syndrome (H-ARS, 2-6 Gy), gastrointestinal acute radiation syndrome (GI-ARS, 6-8 Gy) and neurovascular acute radiation syndrome (>10 Gy). Patients with neurovascular acute radiation syndrome will die within a few days. At present, the treatment of ARS mainly focuses on H-ARS and GI-ARS, and the main cause of death is the serious damage to the hematopoietic system and the gastrointestinal system caused by acute strong radiation. At present, the US FDA has only approved three biological drugs Leukine (sargramostim), Neupogen (filgrastim) and Neulasta (pegfilgrastim) to increase the indications for the treatment of H-ARS, in order to improve the survival rate of H-ARS patients exposed to acute radiation. The three biological drugs belong to recombinant human granulocyte-macrophage colony-stimulating factor, which can stimulate the growth and activation of various immune cells, and promote the proliferation and differentiation of hematopoietic progenitor cells. However, biological drugs generally have problems such as high production and storage cost, poor injection compliance and the possibility of causing harmful immune reactions. SUMMARY
[0003] In a first aspect, a class of 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivatives is provided, which has a structure as shown in formula I,
[0004]
[0005] wherein R1 is selected from H, halogen, alkoxy, alkyl; R2 is selected from H, alkyl; R3 is selected from H, halogen, alkylamine; R4 is selected from H, nitro, alkoxycarbonyl; R5 is selected from any one of H, halogen, nitro, alkylamine, alkoxycarbonyl; R5 is preferably nitro.
[0006] R3 is selected from halogen, preferably F.
[0007] R1 is selected from H, halogen, alkoxy, alkyl; R2 is selected from H, alkyl; R4 is selected from H.
[0008] R3 is selected from H; R1 is selected from H, alkyl; R2 is selected from H; R4 is selected from nitro.
[0009] R3 is selected from H; R1 is selected from halogen, alkyl; R2 is selected from H, alkyl; R4 is selected from alkoxycarbonyl.
[0010] The alkoxyl group is methoxyl, ethoxyl, propoxyl, isopropoxyl; preferably methoxyl or ethoxyl.
[0011] The alkyl group is methyl, ethyl, propyl, butyl, isobutyl or tert-butyl; preferably methyl or tert-butyl;
[0012] The alkylamine group is methylamine, ethylamine, propylamine or isopropylamine; preferably methylamine or ethylamine.
[0013] The alkoxycarbonyl group is methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl or isopropoxycarbonyl; preferably methoxycarbonyl or isopropoxycarbonyl.
[0014] comprises any one of the following:
[0015] 3-(2H-benzopyran-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4-oxadiazole;
[0016] 3-(6-fluoro-2H-benzopyran-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4-oxadiazole;
[0017] 3-(6,8-di-tert-butyl-2H-benzopyran-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4-oxadiazole;
[0018] 3-(6-chloro-2H-benzopyran-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4-oxadiazole;
[0019] 3-(6-methoxy-2H-benzopyran-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4-oxadiazole;
[0020] 3-(2H-benzopyran-3-yl)-5-(3,5-dinitrophenyl)-1,2,4-oxadiazole;
[0021] 3-(2H-benzopyran-3-yl)-5-(3-methoxycarbonyl-5-nitrophenyl)-1,2,4-oxadiazole;
[0022] 3-(6-fluoro-2H-benzopyran-3-yl)-5-(3-methoxycarbonyl-5-nitrophenyl)-1,2,4-oxadiazole;
[0023] 3-(6-fluoro-2H-benzopyran-3-yl)-5-(2-methylamino-5-nitrophenyl)-1,2,4-oxadiazole;
[0024] 3-(6-chloro-2H-chromen-3-yl)-5-(3-methoxycarbonyl-5-nitrophenyl)-1,2,4- oxadiazole;
[0025] 3-(6-chloro-2H-chromen-3-yl)-5-(3-methoxycarbonyl-5-nitrophenyl)-1,2,4- oxadiazole;
[0026] 3-(6-chloro-2H-chromen-3-yl)-5-(3-methoxycarbonyl-5-nitrophenyl)-1,2,4- oxadiazole;
[0027] 3-(6-chloro-2H-chromen-3-yl)-5-(3-methoxycarbonyl-5-nitrophenyl)-1,2,4- oxadiazole;
[0028] 3-(6-chloro-2H-chromen-3-yl)-5-(3-methoxycarbonyl-5-nitrophenyl)-1,2,4- oxadiazole;
[0029] 3-(6-chloro-2H-chromen-3-yl)-5-(3-methoxycarbonyl-5-nitrophenyl)-1,2,4- oxadiazole;
[0030] 3-(6-chloro-2H-chromen-3-yl)-5-(3-methoxycarbonyl-5-nitrophenyl)-1,2,4- oxadiazole;
[0031] 3-(6-chloro-2H-chromen-3-yl)-5-(3-methoxycarbonyl-5-nitrophenyl)-1,2,4- oxadiazole;
[0032] 3-(6-chloro-2H-chromen-3-yl)-5-(3-methoxycarbonyl-5-nitrophenyl)-1,2,4- oxadiazole;
[0033] 3-(6-chloro-2H-chromen-3-yl)-5-(3-methoxycarbonyl-5-nitrophenyl)-1,2,4- oxadiazole;
[0034] 3-(6-chloro-2H-chromen-3-yl)-5-(3-methoxycarbonyl-5-nitrophenyl)-1,2,4- oxadiazole.
[0035] In a second aspect, the present application provides a composition comprising the above-mentioned 3-(2H-chromen-3-yl)-5-phenyl-1,2,4-oxadiazole derivative, its geometric isomer, its pharmaceutically acceptable salt, its hydrate or its solvate, and a pharmaceutically acceptable carrier or excipient.
[0036] In a third aspect, the present application provides use of the above-mentioned 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivative or the above-mentioned composition in the preparation of a medicament for preventing and / or treating ionizing radiation damage.
[0037] In a fourth aspect, the present application provides use of the above-mentioned 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivative or the above-mentioned composition in the preparation of an antitumor medicament, preferably for cervical cancer cells (Hela cells), breast cancer cells (MCF-7 cells), liver cancer cells (HepG2) and non-small cell lung cancer cells (A549 cells), etc.
[0038] The 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivative provided by the present application is a small molecule TLR2 / 1 agonist, which can have an anti-radiation effect by activating the expression of related anti-radiation cytokines in vivo, and has the characteristics of high efficiency, low toxicity and stable quality. In addition, the compound also shows an inhibitory effect on the proliferation of various cancer cells, which provides a new direction for the development of new anti-radiation drugs and antitumor drugs with new structures. BRIEF DESCRIPTION OF DRAWINGS
[0039] Figure 1 The figure shows the comparison of NF-κB agonistic activity of compounds W-1 and W-2 on HEK293T cells expressing hTLR2 / 1 constructed by transient co-transfection.
[0040] Figure 2 The figure shows the survival curve of mice 30 days after 8.5 Gy irradiation.
[0041] Figures 3-5 The figure shows the H NMR chart, C NMR chart and MS chart of compound W-2. 1 H NMR chart, 13 C NMR chart and MS chart. DETAILED DESCRIPTION
[0042] TERMS
[0043] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs.
[0044] Unless otherwise indicated, the present application employs conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the skill of the art. Unless specific definitions are provided, the nomenclature utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those known in the art. In general, the aforesaid techniques and procedures employ, unless otherwise stated, conventional methods that are well known in the art.
[0045] The term "alkyl" refers to an aliphatic hydrocarbon group, which can be straight-chain or branched. Depending on the structure, alkyl can be a monovalent group or a divalent group (i.e., alkylene). In the present application, alkyl is preferably an alkyl group having 1 to 8 carbon atoms, more preferably a "lower alkyl" group having 1 to 6 carbon atoms, and even more preferably an alkyl group having 1 to 4 carbon atoms. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, and the like. It is to be understood that "alkyl" as referred to herein includes all possible configurations and conformations of such alkyl groups, for example, "propyl" as referred to herein includes n-propyl and i-propyl, "butyl" includes n-butyl, i-butyl, and t-butyl, "pentyl" includes n-pentyl, i-pentyl, neopentyl, t-pentyl, and amyl, and the like.
[0046] The term "alkoxy" refers to -O-alkyl, wherein alkyl is as defined herein. Typical alkoxyl groups include, but are not limited to, methoxy, ethoxy, propyloxy, butyloxy, pentyloxy, hexyloxy, and the like.
[0047] The term "cycloalkyl" refers to a monocyclic or polycyclic group containing only carbon and hydrogen. Cycloalkyl groups include groups having from 3 to 12 ring atoms. Depending on the structure, cycloalkyl can be a monovalent group or a divalent group (e.g., cycloalkylene). In the present application, cycloalkyl is preferably a cycloalkyl group having 3 to 8 carbon atoms, more preferably a "lower cycloalkyl" group having 3 to 6 carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and adamantyl.
[0048] The term "aryl" refers to a planar ring having a system of delocalized π electrons and containing 4n+2 π electrons, where n is an integer. The aryl ring can be composed of five, six, seven, eight, nine, or more than nine atoms. The aryl group can be optionally substituted. The term "aryl" includes carbocyclic aryl (e.g., phenyl) and heterocyclic aryl (or "heteroaryl" or "heteroaromatic") groups (e.g., pyridine). The term includes monocyclic or fused ring polycyclic (i.e., rings that share adjacent pairs of carbon atoms) groups.
[0049] As used herein, the term "aryl" refers to a ring in which each of the atoms that make up the ring is a carbon atom. The aryl ring can be composed of five, six, seven, eight, nine, or more than nine atoms. The aryl group can be optionally substituted. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, phenanthryl, anthryl, fluorenyl, and indenyl. Depending on the structure, the aryl group can be a monovalent radical or a divalent radical (i.e., an arylene group).
[0050] The term "aryloxy" refers to -O-aryl, wherein aryl is as defined herein.
[0051] The term "heteroaryl" refers to an aryl group that includes one or more ring heteroatoms selected from nitrogen, oxygen, and sulfur. N-containing "heteroaryl" moieties refer to aromatic groups in which at least one of the ring-forming atoms is a nitrogen atom. Depending on the structure, the heteroaryl group can be a monovalent radical or a divalent radical (i.e., a heteroarylene group). Examples of heteroaryl groups include, but are not limited to, pyridyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furanyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, naphthyridinyl, furopyridinyl, and the like.
[0052] As used herein, the term "heteroalkyl" refers to an alkyl group as defined herein in which one or more of the skeletal chain atoms are heteroatoms, such as oxygen, nitrogen, sulfur, silicon, phosphorus, or a combination thereof. The heteroatom(s) can be located anywhere within the heteroalkyl group or at the point of attachment of the heteroalkyl group to the remainder of the molecule.
[0053] The term "heterocycloalkyl" or "heterocyclyl" as used herein refers to a non-aromatic ring in which one or more of the atoms that make up the ring is a heteroatom selected from nitrogen, oxygen, and sulfur. The heterocycloalkyl ring can be composed of three, four, five, six, seven, eight, nine, or more than nine atoms. The heterocycloalkyl ring can be optionally substituted. Examples of heterocycloalkyl groups include, but are not limited to, lactams, lactones, cyclic imides, cyclic thioimides, cyclic carbamates, tetrahydrothiopyran, 4H-pyran, tetrahydropyran, piperidine, 1,3-dioxine, 1,3-dioxane, 1,4-dioxine, 1,4-dioxane, piperazine, 1,3- oxathiane, 1,4-oxathiine, 1,4-oxathiane, tetrahydro-l,4-thiazine, 2H-l,2-oxazine, maleimide, succinimide, barbituric acid, thiobarbituric acid, dioxopiperazine, hydantoin, dihydrouracil, morpholine, trioxane, hexahydro-l,3,5-triazine, tetrahydrothiophene, tetrahydrofuran, pyrrolin, pyrrolidine, imidazolidine, pyrrolidinone, pyrazoline, pyrazolidine, imidazoline, imidazolidine, 1,3-dioxole, 1,3-dioxolane, 1,3-dithiole, 1,3-dithiolane, isoxazoline, isoxazolidine, oxazoline, oxazolidine, oxazolidinone, thiazoline, thiazolidine, and 1,3-oxathiolane. Depending on the structure, the heterocycloalkyl group can be a monovalent radical or a divalent radical (i.e., a heterocycloalkylene group).
[0054] The term "halo" or "halogen" refers to fluorine, chlorine, bromine, and iodine.
[0055] The terms "haloalkyl," "haloalkoxy," and "haloheteroalkyl" include structures in which at least one hydrogen of an alkyl, alkoxy, or heteroalkyl group is replaced with a halogen atom. In certain embodiments, if two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are the same or different from each other.
[0056] The term "amino" refers to a -NH2 group.
[0057] The term "hydroxyl" refers to an -OH group.
[0058] The term "cyano" refers to a -CN group.
[0059] The term "ester" refers to a chemical moiety having the formula -COOR, where R is selected from alkyl, cycloalkyl, aryl, heteroaryl (attached through a ring carbon), and heterocyclyl (attached through a ring carbon).
[0060] The term "amide" or "amido" refers to a -NR-CO-R' group, where R and R' are each independently hydrogen or alkyl.
[0061] The term "amido" or "amidino" refers to a -CO-NH2 group.
[0062] The term "alkylaminoacyl" or "alkylaminocarbonyl" refers to a -CO-NH-R group, wherein R is alkyl as defined herein.
[0063] The term "optionally" means that the event or events that follow can or can not occur and includes both the event occurring and the event not occurring. The term "optionally substituted" or "substituted" means that the group in question can be substituted with one or more additional groups, each and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, hydroxy, alkoxy, cyano, halogen, amido, nitro, haloalkyl, amino, mesyl, alkylcarbonyl, alkoxycarbonyl, heteroarylalkyl, heterocycloalkylalkyl, aminoacyl, amino protecting group, and the like. Among them, the amino protecting group is preferably selected from pivaloyl, t-butoxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzyl, p-methoxybenzyl, allyloxycarbonyl, trifluoroacetyl and the like.
[0064] Toll-like receptors (TLRs) are a class of proteins that recognize pathogen-associated molecular patterns (PAMPs) and endogenous damage-associated molecular patterns (DAMPs) and are involved in the regulation of the innate immune system. TLRs are type I transmembrane proteins composed of an extracellular domain, a transmembrane domain and an intracellular domain. After the ligand of Toll-like receptor is triggered by binding with the receptor, the TLR homodimer or heterodimer activates the intracellular Toll / IL-1R receptor (TIR) domain to cause downstream signal cascade reaction, and then activates the related signal pathway. There are 10 members in the human TLR family, among which TLR1, TLR2, TLR5, TLR10 and TLR6 are located on the cell membrane surface, TLR3, TLR7, TLR8 and TLR9 are located on the membrane of endoplasmic reticulum, endosome and lysosome, and TLR4 is expressed on both the cell membrane surface and the intracellular membrane. Diseases related to TLRs mainly include infection, cancer, inflammation, neurodegenerative diseases and autoimmune diseases. In recent years, it has been found that TLR agonists can induce the expression of various cytokines, and the inventors found that these cytokines include granulocyte colony-stimulating factor (G-CSF), interleukin 6 (IL-6), etc., which are cytokines with radiation protection effect, and can alleviate the reduction of white blood cells and platelets caused by radiation, so the inventors boldly conjectured that TLR might be a target for anti-radiation.
[0065] TLR2 is the most PAMPs-recognizing member in the TLR family, which can recognize ligands by forming a heterodimer with TLR1 or TLR6 to initiate signal transduction. TLR2 mainly recognizes lipopeptides, which are the components of various microbial cell walls, so lipopeptides and their derivatives are the earliest discovered TLR2 agonists. At present, there are only a few reports of small molecule TLR2 / 1 agonists in the literature, and the 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivatives represented by formula I provided by the present application have TLR2 / 1 agonistic activity and have good prospects in the preparation of anti-radiation drugs and anti-tumor drugs.
[0066] The present application provides a compound, which is a 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivative, and the structure is formula I:
[0067]
[0068] wherein R1 is selected from H, halogen (such as F, Cl, Br), alkoxy, alkyl; R2 is selected from H, alkyl; R3, R4, R5 are independently selected from any one of H, halogen (such as F, Cl, Br), alkylamine, nitro, alkoxycarbonyl.
[0069] For example, R1 is selected from any one of H, F, Cl, Br, OCH3, C(CH3)3; R2 is selected from H, C(CH3)3; R3, R4, R5 are independently selected from any one of H, F, Cl, Br, NHCH3, NO2, COOCH3.
[0070] The above 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivatives also include geometric isomers of the compound of formula I, pharmaceutically acceptable salts thereof, hydrates or solvates thereof, and pharmaceutical compositions of pharmaceutically acceptable carriers or excipients. Among them: isomers or hydrates, such as optical isomers or racemic compounds; pharmaceutically acceptable salts can be sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, hydrochloride, bromide, iodide, acetate, propionate, octanoate, acrylate, formate, isobutyrate, heptanoate, decanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, 2-butine-1,4-dioate, 3-cyclohexene-2,5-dioate, benzoate, chlorobenzoate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hippurate, β-hydroxybutyrate, glycolate, maleate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, glutamate, arginate, lysinate, etc. of the compound of formula I, preferably hydrochloride and phosphate.
[0071] The 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivatives provided by the present application can be administered orally or parenterally. Oral administration can be in the form of tablets, pills, granules, capsules, coated preparations, oral solutions, emulsions, powders; parenteral administration can be in the form of injections, suppositories, or other suitable forms. The excipients used to manufacture the above dosage forms are all common excipients. The excipients used in solid dosage forms such as tablets, capsules, and coated preparations include starch, gelatin, acacia, silica, polyethylene glycol; the solvents used in liquid dosage forms are water, ethanol, propylene glycol, vegetable oils (such as corn oil, peanut oil, olive oil, etc.), and the like. Other excipients such as surfactants, lubricants, disintegrants, preservatives, flavoring agents, colorants, and the like are also common excipients.
[0072] The compounds of Formula (I) can be synthesized using standard synthetic techniques known to those skilled in the art or using methods known in the art in combination with the methods described herein. Additionally, the solvents, temperatures, and other reaction conditions given herein can be varied by one skilled in the art. As further guidance, the following synthetic methods can also be utilized.
[0073] The reactions can be used in sequence to provide the compounds described herein; or they can be used to synthesize fragments which are subsequently incorporated by the methods described herein and / or methods known in the art.
[0074] Compounds can be synthesized using methods analogous to those described below, by using appropriate alternative starting materials. The starting materials used to synthesize the compounds described herein can be synthesized or can be obtained from commercial sources. The compounds described herein and other related compounds having different substituents can be synthesized using techniques and starting materials known to those skilled in the art. The general methods for preparing the compounds disclosed herein can be derived from reactions known in the art, and the reactions can be modified by reagents and conditions deemed appropriate by those skilled in the art to introduce the various moieties in the molecules provided herein.
[0075] If desired, the reaction products can be isolated and purified using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography, and the like. The products can be characterized using conventional methods, including physical constants and spectral data.
[0076] The present application also provides a method for preparing the compounds of Formula I, the synthesis steps of the 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivatives are as follows:
[0077] Step (1): Synthesis of substituted 3-(N-hydroxymethylcarbamimidoyl)-2H- chromen compound: see Formula 1, substituted 3-cyano-2H-chromen 2.54 mmol was placed in a 25 mL flask, hydroxylamine hydrochloride 0.32 g (4.60 mmol) was added, ethanol 10 mL was added, triethylamine 0.64 mL (4.60 mmol) was added, heated to reflux for 2 hours. The solvent was evaporated under reduced pressure, 20 mL water was added, insoluble solid appeared, suction filtration, water washing, vacuum drying, the product obtained can be directly used for the synthesis of next step.
[0078]
[0079] Step (2): Synthesis of substituted 3-(2H-chromen-3-yl)-5-phenyl-1,2,4-oxadiazole derivative: see Formula 2, substituted benzoic acid compound 1.5 mmol was placed in a 50 mL flask, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) 1.5 mmol was added, 3 mL tetrahydrofuran and 9 mL N-methylpyrrolidone were added, stirring at room temperature for 30 minutes. Substituted 3-(N-hydroxymethylcarbamimidoyl)-2H-chromen 1.0 mmol was added, heated to 150°C for 2 hours. After cooling to room temperature, the reaction mixture was diluted with 30 mL water, successively extracted with 10 mL ethyl acetate for three times, the ethyl acetate extracts were combined and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure to obtain a crude product. The crude product was separated by silica gel column chromatography to obtain a pure product.
[0080]
[0081] The present application will be further described in detail in connection with specific examples, and the present application will be further illustrated, but these examples are by no means limiting to the present application.
[0082] The following specific examples illustrate the preparation of the compounds of the present application and their properties, and the examples are not exhaustive. The reagents used in the examples are commercially available or synthesized according to the related literature, the nuclear magnetic resonance spectrum is determined by Bruker 600M superconducting nuclear magnetic instrument, and the ESI mass spectrum is determined by Agilent 1260-G6230A mass spectrometer of USA.
[0083] Example 1: Synthesis of 3-(2H-chromen-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4- oxadiazole (W-1)
[0084]
[0085] 3-cyano-2H-chromen-399 mg (2.54 mmol) was placed in a 25 mL flask, hydroxylamine hydrochloride 0.32 g (4.60 mmol) was added, ethanol 10 mL was added, triethylamine 0.64 mL (4.60 mmol) was added, and heated to reflux for 2 hours. The solvent was evaporated under reduced pressure, 20 mL of water was added, and insoluble solid appeared, which was filtered, washed with water, and dried under vacuum to give a white solid 0.443 g, yield 91.7%. The product was used directly for the next step of synthesis.
[0086] Synthesis of 3-(2H-chromen-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4-oxadiazole:
[0087]
[0088] 2-fluoro-5-nitrobenzoic acid 278 mg (1.5 mmol) was placed in a 50 mL flask, DMTMM 415 mg (1.5 mmol) was added, 3 mL of tetrahydrofuran and 9 mL of N-methylpyrrolidone were added, and stirred at room temperature for 30 minutes. 3-(N-hydroxylcarbamimidoyl)-2H-chromen 190 mg (1.0 mmol) was added, and heated to react at 150 °C for 2 hours. After cooling to room temperature, the reaction mixture was diluted with 30 mL of water, and successively extracted with 10 mL of ethyl acetate three times, and the ethyl acetate extract was combined, and dried over anhydrous sodium sulfate. It was evaporated under reduced pressure to give a crude product. The crude product was separated by silica gel column chromatography to give a yellow solid 0.282 g, yield 83.1%, m.p. 181-182 °C.
[0089] 1 H NMR (600 MHz, DMSO-d6) δ 8.89 (dd, J = 6.1, 2.9 Hz, 1H), 8.61 (dt, J = 9.1, 3.4 Hz, 1H), 7.85 (t, J = 9.5 Hz, 1H), 7.68 (s, 1H), 7.43 (d, J = 7.5 Hz, 1H), 7.27 (t, J = 7.7 Hz, 1H), 6.98 (t, J = 7.4 Hz, 1H), 6.89 (d, J = 8.1 Hz, 1H), 5.20 (s, 2H). 13C NMR (151 MHz, DMSO-d6) δ 170.83 (d, J = 4.53 Hz), 165.95, 163.54 (d, J = 268.78 Hz), 154.51, 144.64 (d, J = 3.02 Hz), 131.85, 131.05 (d, J = 12.08 Hz), 129.28, 128.97, 126.81 (d, J = 3.02 Hz), 122.41, 121.35, 119.73 (d, J = 24.16 Hz), 118.78, 116.15, 113.39 (d, J = 13.59 Hz), 64.19. MS (ESI-TOF) m / z: 362.33 (M+Na) + .
[0090] Example 2: Synthesis of 3-(6-fluoro-2H-chromen-3-yl)-5-(2-fluoro-5-nitrophenyl)- 1,2,4-oxadiazole (W-2)
[0091] Synthesis of 3-(N-hydroxymethylcarbamimidoyl)-6-fluoro-2H-chromene:
[0092]
[0093] 3-cyano-6-fluoro-2H-chromene 445 mg (2.54 mmol) was placed in a 25 mL flask, hydroxylamine hydrochloride 0.32 g (4.60 mmol) was added, ethanol 10 mL was added, triethylamine 0.64 mL (4.60 mmol) was added, and heated to reflux for 2 hours. The solvent was evaporated under reduced pressure, 20 mL of water was added, and insoluble solid appeared, which was filtered, washed with water, and dried under vacuum to give a light yellow solid 0.476 g, with a yield of 90.0%. The product obtained can be directly used for the synthesis of the next step.
[0094] Synthesis of 3-(6-fluoro-2H-chromen-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4-oxadiazole:
[0095]
[0096] 2-Fluoro-5-nitrobenzoic acid 278 mg (1.5 mmol) was placed in a 50 mL flask, DMTMM 415 mg (1.5 mmol) was added, 3 mL of tetrahydrofuran and 9 mL of N-methylpyrrolidone were added, stirring at room temperature for 30 minutes. 3-(N- hydroxymethylcarbamimidoyl)-6-fluoro-2H-benzopyran 208 mg (1.0 mmol) was added, heating the reaction at 150 °C for 2 hours. After cooling to room temperature, the reaction mixture was diluted with 30 mL of water, successively extracted three times with 10 mL of ethyl acetate each time, the ethyl acetate extracts were combined and dried over anhydrous sodium sulfate. It was evaporated under reduced pressure to obtain the crude product. The crude product was separated by column chromatography on silica gel to obtain a yellow solid 0.291 g, yield 81.4%, m.p. 184-186 °C.
[0097] 1 H NMR (600 MHz, DMSO-d6) δ 8.89 (dd, J = 5.9, 2.9 Hz, 1H), 8.62 (ddd, J = 9.1, 3.9, 2.9 Hz, 1H), 7.85 (t, J = 9.5 Hz, 1H), 7.69 (d, J = 1.6 Hz, 1H), 7.36 (dd, J = 8.7, 3.1 Hz, 1H), 7.10 (td, J = 8.7, 3.1 Hz, 1H), 6.92 (dd, J = 8.9, 4.5 Hz, 1H), 5.19 (d, J = 1.4 Hz, 2H). 13 C NMR (151 MHz, DMSO-d6) δ 170.96 (d, J = 4.4 Hz), 165.79, 163.54 (d, J = 268.78 Hz), 157.33 (d, J = 237.07 Hz), 150.66, 144.64 (d, J = 2.8 Hz), 131.10 (d, J = 11.1 Hz), 128.19, 126.79 (d, J = 2.9 Hz), 122.51 (d, J = 9.06 Hz), 120.26, 119.75 (d, J = 22.65 Hz), 117.92 (d, J = 24.16 Hz), 117.43 (d, J = 8.2 Hz), 115.07 (d, J = 24.16 Hz), 113.34 (d, J = 13.59 Hz), 64.31. MS (ESI-TOF) m / z: 376.30 (M+H3O) + .
[0098] Example 3: Synthesis of 3-(6,8-di-tert-butyl-2H-benzopyran-3-yl)-5-(2-fluoro-5- nitrophenyl)-1,2,4-oxadiazole (W-3)
[0099] 3-(N-hydroxymethylcarbamimidoyl)-6,8-di-tert-butyl-2H-benzopyran synthesis:
[0100]
[0101] 3-cyano-6,8-di-tert-butyl-2H-chromen 684 mg (2.54 mmol) was placed in a 25 mL flask, hydroxylamine hydrochloride 0.32 g (4.60 mmol) was added, ethanol 10 mL was added, triethylamine 0.64 mL (4.60 mmol) was added, heated to reflux for 2 hours. The solvent was evaporated under reduced pressure, 20 mL water was added, insoluble solid appeared, suction filtered, washed with water, vacuum dried, gave a light yellow solid 0.698 g, yield 90.9%. The product was used directly for the next step synthesis.
[0102] Synthesis of 3-(6,8-di-tert-butyl-2H-chromen-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4- oxadiazole:
[0103]
[0104] 2-Fluoro-5-nitrobenzoic acid 278 mg (1.5 mmol) was placed in a 50 mL flask, DMTMM 415 mg (1.5 mmol) was added, 3 mL tetrahydrofuran and 9 mL N-methylpyrrolidone were added, stirred at room temperature for 30 minutes. 3-(N- hydroxymethylcarbamimidoyl)-6,8-di-tert-butyl-2H-chromen 302 mg (1.0 mmol) was added, heated to 150 °C for 2 hours. After cooling to room temperature, the reaction mixture was diluted with 30 mL water, successively extracted with 10 mL ethyl acetate three times, the ethyl acetate extracts were combined, dried over anhydrous sodium sulfate. Evaporated under reduced pressure to give a crude product. The crude product was separated by silica gel column chromatography to give a yellow solid 0.387 g, yield 85.7%, m.p. 179-181 °C.
[0105] 1 H NMR (600 MHz, Chloroform-d) δ 9.06 (dd, J = 5.9, 2.9 Hz, 1H), 8.43 (ddd, J = 9.1, 4.0, 2.9 Hz, 1H), 7.58 (d, J = 1.4 Hz, 1H), 7.42 (t, J = 9.1 Hz, 1H), 7.25 (d, J = 2.4 Hz, 1H), 7.06 (d, J = 2.4 Hz, 1H), 5.13 (d, J = 1.3 Hz, 2H), 1.35 (s, 9H), 1.25 (s, 9H). 13C NMR (151 MHz, Chloroform-d) δ 170.08 (d, J = 4.7 Hz), 166.52, 163.75 (d, J = 271.80 Hz), 150.96, 143.91, 137.31, 130.68, 129.52 (d, J = 10.5 Hz), 127.07 (d, J = 3.0 Hz), 126.06, 123.39, 121.68, 118.62 (d, J = 22.65 Hz), 118.14, 63.50, 34.78, 34.38, 31.46, 29.75. MS (ESI-TOF) m / z: 452.20 (M+H) + .
[0106] Example 4: Synthesis of 3-(6-chloro-2H-chromen-3-yl)-5-(2-fluoro-5-nitrophenyl)- 1,2,4-oxadiazole (W-4)
[0107] Synthesis of 3-(N-hydroxymethylcarbamimidoyl)-6-chloro-2H-chromene:
[0108]
[0109] 3-cyano-6-chloro-2H-chromene 485 mg (2.54 mmol) was placed in a 25 mL flask, hydroxylamine hydrochloride 0.32 g (4.60 mmol) was added, ethanol 10 mL was added, triethylamine 0.64 mL (4.60 mmol) was added, and heated to reflux for 2 hours. The solvent was evaporated under reduced pressure, 20 mL of water was added, and insoluble solid appeared, which was filtered, washed with water, and dried under vacuum to obtain a yellow solid 0.467 g with a yield of 81.9%. The product obtained can be directly used for the synthesis of the next step.
[0110] Synthesis of 3-(6-chloro-2H-chromen-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4- oxadiazole:
[0111]
[0112] 2-Fluoro-5-nitrobenzoic acid 278 mg (1.5 mmol) was placed in a 50 mL flask, DMTMM 415 mg (1.5 mmol) was added, 3 mL of tetrahydrofuran and 9 mL of N-methylpyrrolidone were added, stirred at room temperature for 30 minutes. 3-(N- hydroxymethylcarbamimidoyl)-6-chloro-2H-chromen 224 mg (1.0 mmol) was added, heated to 150 °C for 2 hours. After cooling to room temperature, the reaction mixture was diluted with 30 mL of water, successively extracted with 10 mL of ethyl acetate three times, the ethyl acetate extract was combined and dried over anhydrous sodium sulfate. Evaporated under reduced pressure to obtain a crude product. The crude product was separated by silica gel column chromatography to obtain a yellow solid 0.315 g, yield 84.3%, m.p. 233-235 °C.
[0113] 1 H NMR (600 MHz, DMSO-d6) δ 8.89 (dd, J = 5.9, 2.9 Hz, 1H), 8.63 (dt, J = 9.2, 3.1 Hz, 1H), 7.86 (t, J = 9.5 Hz, 1H), 7.70 (s, 1H), 7.56 (d, J = 2.6 Hz, 1H), 7.29 (dd, J = 8.6, 2.6 Hz, 1H), 6.92 (d, J = 8.6 Hz, 1H), 5.23 (s, 2H). 13 C NMR (151 MHz, DMSO-d6) δ 171.01 (d, J = 4.2 Hz), 165.77, 163.55 (d, J = 285.39 Hz), 162.67, 153.26, 144.68, 131.16, 128.44, 127.83, 126.86 (d, J = 2.9 Hz), 125.93, 122.99, 120.15, 119.76 (d, J = 12.08 Hz), 117.95, 113.39 (d, J = 13.59 Hz), 64.45. MS (ESI-TOF) m / z: 374.36 (M+H) + .
[0114] Example 5: Synthesis of 3-(6-methoxy-2H-chromen-3-yl)-5-(2-fluoro-5-nitrophenyl)- 1,2,4-oxadiazole (W-5)
[0115] Synthesis of 3-(N-hydroxymethylcarbamimidoyl)-6-methoxy-2H-chromene:
[0116]
[0117] 3-cyano-6-methoxy-2H-chromen 475 mg (2.54 mmol) was placed in a 25 mL flask, hydroxylamine hydrochloride 0.32 g (4.60 mmol) was added, ethanol 10 mL was added, triethylamine 0.64 mL (4.60 mmol) was added, heated to reflux for 2 hours. The solvent was evaporated under reduced pressure, 20 mL water was added, insoluble solid appeared, suction filtered, washed with water, dried in vacuum, white solid 0.433 g was obtained, yield 77.4%. The product can be used directly for the next step synthesis.
[0118] Synthesis of 3-(6-methoxy-2H-chromen-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4- oxadiazole:
[0119]
[0120] 2-fluoro-5-nitrobenzoic acid 278 mg (1.5 mmol) was placed in a 50 mL flask, DMTMM 415 mg (1.5 mmol) was added, 3 mL tetrahydrofuran and 9 mL N- methylpyrrolidone were added, stirred at room temperature for 30 minutes. 3-(N- hydroxymethylcarbamimidoyl)-6-methoxy-2H-chromen 220 mg (1.0 mmol) was added, heated to 150 °C for 2 hours. After cooling to room temperature, the reaction mixture was diluted with 30 mL water, successively extracted with 10 mL ethyl acetate three times, the ethyl acetate extract was combined, dried over anhydrous sodium sulfate. Evaporated under reduced pressure to obtain the crude product. The crude product was separated by silica gel column chromatography to obtain yellow solid 0.313 g, yield 84.8%, m.p. 215-216 °C.
[0121] 1 H NMR (600 MHz, DMSO-d6) δ 8.91 (dd, J = 5.9, 2.9 Hz, 1H), 8.63 (dt, J = 9.2, 3.6 Hz, 1H), 7.86 (t, J = 9.5 Hz, 1H), 7.70 (s, 1H), 7.11 (s, 1H), 6.86 (s, 2H), 5.14 (s, 2H), 3.73 (s, 3H). 13 C NMR (151 MHz, DMSO-d6) δ 166.03, 154.56, 148.40, 144.70, 131.12, 129.28, 126.89, 122.10, 119.83, 119.67, 119.60, 117.37, 116.88, 113.74, 64.19, 55.97. MS (ESI-TOF) m / z: 370.08 (M+H) + .
[0122] Example 6: Synthesis of 3-(2H-benzopyran-3-yl)-5-(3,5-dinitrophenyl)-1,2,4- oxadiazole (W-6)
[0123]
[0124] Following the procedure of Example 1, only replacing 2-fluoro-5-nitrobenzoic acid with 3,5-dinitrobenzoic acid, gave yellow powder 0.199 g, yield 54.3%, m.p. 239-242 °C.
[0125] 1 H NMR (600 MHz, Chloroform-d) δ 9.34 (d, J = 2.1 Hz, 2H), 9.28 (t, J = 2.1 Hz, 1H), 7.65 (s, 1H), 7.30 - 7.21 (m, 2H), 6.99 (td, J = 7.4, 1.1 Hz, 1H), 6.92 (d, J = 7.9 Hz, 1H), 5.27 (d, J = 1.4 Hz, 2H). 13 C NMR (151 MHz, Chloroform-d) δ 171.17, 166.97, 154.79, 149.20, 131.59, 129.84, 128.55, 127.87, 127.36, 122.06, 122.02, 121.07, 118.22, 116.24, 64.27. MS (ESI-TOF) m / z: 367.07 (M+H) + .
[0126] Example 7: Synthesis of 3-(2H-benzopyran-3-yl)-5-(3-methoxycarbonyl-5- nitrophenyl)-1,2,4-oxadiazole (W-7)
[0127]
[0128] Following the procedure of Example 1, only replacing 2-fluoro-5-nitrobenzoic acid with 3-methoxycarbonyl-5-nitrobenzoic acid, gave light yellow powder 0.122 g, yield 32.2%, m.p. 200-202 °C.
[0129] 1H NMR (600 MHz, Chloroform-d) δ 9.18 (t, J = 1.9 Hz, 1H), 9.11 (t, J = 1.6 Hz, 1H), 9.06 (t, J = 1.9 Hz, 1H), 7.60 (s, 1H), 7.25 - 7.20 (m, 2H), 6.96 (t, J = 7.4 Hz, 1H), 6.89 (d, J = 8.1 Hz, 1H), 5.25 (d, J = 1.4 Hz, 2H), 4.07 (s, 3H). 13 C NMR (151 MHz, Chloroform-d) δ 172.31, 166.72, 163.84, 154.71, 148.86, 134.14, 133.33, 131.37, 129.27, 128.45, 127.88, 126.61, 126.17, 121.96, 121.14, 118.58, 116.16, 64.33, 53.31. MS (ESI-TOF) m / z: 380.09 (M+H) + .
[0130] Example 8: Synthesis of 3-(6-fluoro-2H-chromen-3-yl)-5-(3-methoxycarbonyl-5- nitrophenyl)-1,2,4-oxadiazole (W-8)
[0131]
[0132] Following the procedure of Example 2, substituting 3-methoxycarbonyl-5- nitrobenzoic acid for 2-fluoro-5-nitrobenzoic acid, there was obtained 0.324 g of a light yellow powder, yield 81.6%, m.p. 205-207°C.
[0133] 1 H NMR (600 MHz, Chloroform-d) δ 9.18 (t, J = 1.9 Hz, 1H), 9.11 (t, J = 1.6 Hz, 1H), 9.06 (t, J = 1.9 Hz, 1H), 7.60 (s, 1H), 7.25 - 7.20 (m, 2H), 6.96 (t, J = 7.4 Hz, 1H), 6.89 (d, J = 8.1 Hz, 1H), 5.25 (d, J = 1.4 Hz, 2H), 4.07 (s, 3H). 13C NMR (151 MHz, Chloroform-d) δ 172.50, 166.54, 163.83, 157.60 (d, J = 241.60 Hz), 150.65, 148.90, 134.17, 133.39, 128.41, 127.97, 126.63, 126.07, 122.06 (d, J = 90.06 Hz), 120.13, 117.56 (d, J = 22.65 Hz), 117.18 (d, J = 7.55 Hz), 114.23 (d, J = 24.16 Hz), 64.42, 53.33. MS (ESI-TOF) m / z: 398.22 (M+H) + .
[0134] Example 9: Synthesis of 3-(6-fluoro-2H-chromen-3-yl)-5-(2-methylamino-5- nitrophenyl)-1,2,4-oxadiazole (W-9)
[0135]
[0136] Following the procedure of Example 2, replacing only 2-fluoro-5-nitrobenzoic acid with 2-methylamino-5-nitrobenzoic acid, a light yellow powder 0.289 g was obtained in 78.5% yield, m.p. 256-259 °C.
[0137] 1 H NMR (600 MHz, Chloroform-d) δ 8.98 (d, J = 2.7 Hz, 1H), 8.46 (s, 1H), 8.32 (dd, J = 9.6, 2.6 Hz, 1H), 7.42 (s, 1H), 7.05 - 6.74 (m, 4H), 5.24 (s, 2H), 3.19 (d, J = 5.0 Hz, 3H). MS (ESI-TOF) m / z: 369.10 (M+H) + .
[0138] Example 10: Synthesis of 3-(6-fluoro-2H-chromen-3-yl)-5-(2-chloro-5-nitrophenyl)- 1,2,4-oxadiazole (W-10)
[0139]
[0140] Following the procedure of Example 2, replacing only 2-fluoro-5-nitrobenzoic acid with 2-chloro-5-nitrobenzoic acid, an orange powder 0.314 g was obtained in 84.0% yield, m.p. 163-165 °C.
[0141] 1H NMR (600 MHz, DMSO-d6) δ 8.87 (d, J = 2.8 Hz, 1H), 8.50 (dd, J = 8.9, 2.8 Hz, 1H), 8.06 (d, J = 8.8 Hz, 1H), 7.66 (s, 1H), 7.34 (dd, J = 8.7, 3.1 Hz, 1H), 7.10 (td, J = 8.7, 3.1 Hz, 1H), 6.91 (dd, J = 8.8, 4.5 Hz, 1H), 5.19 (d, J = 1.5 Hz, 2H). 13 C NMR (151 MHz, DMSO-d6) δ 172.48, 165.81, 158.13, 156.56, 150.68, 146.84, 139.49, 133.60, 128.82, 128.23, 128.22, 127.32, 124.10, 122.54, 122.48, 120.31, 118.02, 117.87, 117.48, 117.42, 115.16, 115.00, 64.32. MS (ESI-TOF) m / z: 374.05 (M+H) + .
[0142] Example 11: Synthesis of 3-(6-chloro-2H-chromen-3-yl)-5-(3,5-dinitrophenyl)- 1,2,4-oxadiazole (W-11)
[0143]
[0144] Following the procedure of Example 4, only replacing 2-fluoro-5-nitrobenzoic acid with 3,5-dinitrobenzoic acid, a yellow powder 0.307 g, 76.6% yield, m.p. 218-219 °C was obtained.
[0145] 1 H NMR (600 MHz, Chloroform-d) δ 9.33 (d, J = 2.1 Hz, 2H), 9.28 (t, J = 2.1 Hz, 1H), 7.57 (s, 1H), 7.20 (dq, J = 4.7, 2.5 Hz, 2H), 6.88 - 6.83 (m, 1H), 5.26 (d, J = 1.5 Hz, 2H). 13 C NMR (151 MHz, Chloroform-d) δ 171.35, 166.70, 153.23, 149.22, 131.09, 128.57, 127.87, 127.83, 127.20, 126.80, 122.26, 122.12, 119.50, 117.58, 64.41. MS (ESI-TOF) m / z: 401.37 (M+H) + .
[0146] Example 12: Synthesis of 3-(6-chloro-2H-chromen-3-yl)-5-(2-chloro-5-nitrophenyl)- 1,2,4-oxadiazole (W-12)
[0147]
[0148] Following the procedure of Example 4, only replacing 2-fluoro-5-nitrobenzoic acid with 2-chloro-5-nitrobenzoic acid, gave yellow powder 0.308 g, 79.8% yield, m.p. 216-218 °C.
[0149] 1 H NMR (600 MHz, Chloroform-d) δ 9.02 (d, J = 2.7 Hz, 1H), 8.38 (dd, J = 8.8, 2.7 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 7.53 (s, J = 1.2 Hz, 1H), 7.19-7.17 (m, 2H), 6.85-6.83 (m, 1H), 5.26 (d, J = 1.5 Hz, 2H). 13 C NMR (151 MHz, Chloroform-d) δ 172.07, 166.04, 153.19, 146.54, 140.58, 132.88, 130.86, 128.03, 127.76, 127.42, 127.09, 126.71, 124.56, 122.40, 119.86, 117.50, 64.51. MS (ESI-TOF) m / z: 390.02 (M+H) + .
[0150] Example 13: Synthesis of 3-(6-methoxy-2H-chromen-3-yl)-5-(2-chloro-5-nitrophenyl)- 1,2,4-oxadiazole (W-13)
[0151]
[0152] Following the procedure of Example 5, only replacing 2-fluoro-5-nitrobenzoic acid with 2-chloro-5-nitrobenzoic acid, gave yellow powder 0.308 g, 79.8% yield, m.p. 216-218 °C.
[0153] 1H NMR (600 MHz, Chloroform-d) δ 9.03 (d, J = 2.7 Hz, 1H), 8.37 (dd, J = 8.8, 2.7 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 7.59 (s, 1H), 6.87 - 6.77 (m, 3H), 5.21 (s, 2H), 3.80 (s, 3H). 13 CNMR (151 MHz, Chloroform-d) δ 171.92, 166.32, 154.47, 148.71, 146.52, 140.55, 132.83, 129.35, 127.32, 127.10, 124.70, 121.82, 119.48, 116.99, 116.83, 112.78, 64.38, 55.80. MS (ESI-TOF) m / z: 386.05 (M+H) + .
[0154] Example 14: Synthesis of 3-(8-tert-butyl-2H-chromen-3-yl)-5-(3,5-dinitrophenyl)- 1,2,4-oxadiazole (W-14)
[0155] Synthesis of 3-(N-hydroxymethylcarbamimidoyl)-8-tert-butyl-2H-chromene:
[0156]
[0157] 3-cyano-8-tert-butyl-2H-chromene 542 mg (2.54 mmol) was placed in a 25 mL flask, hydroxylamine hydrochloride 0.32 g (4.60 mmol) was added, ethanol 10 mL was added, triethylamine 0.64 mL (4.60 mmol) was added, heated to reflux for 2 hours. The solvent was evaporated under reduced pressure, 20 mL of water was added, insoluble solid appeared, suction filtration, water washing, vacuum drying, yellow solid 0.597 g was obtained, the yield was 95.4%. The product obtained can be directly used for the synthesis of the next step.
[0158] Synthesis of 3-(8-tert-butyl-2H-chromen-3-yl)-5-(3,5-dinitrophenyl)-1,2,4-oxadiazole:
[0159]
[0160] 3,5-dinitrobenzoic acid 318 mg (1.5 mmol) was placed in a 50 mL flask, DMTMM 415 mg (1.5 mmol) was added, 3 mL of tetrahydrofuran and 9 mL of N-methylpyrrolidone were added, stirring at room temperature for 30 minutes. 3-(N- hydroxymethylamidine)-8-tert-butyl-2H-benzopyran 246 mg (1.0 mmol) was added, heating the reaction at 150 °C for 2 hours. After cooling to room temperature, the reaction mixture was diluted with 30 mL of water, successively extracted with 10 mL of ethyl acetate three times, the ethyl acetate extracts were combined and dried over anhydrous sodium sulfate. It was evaporated under reduced pressure to obtain the crude product. The crude product was separated by column chromatography on silica gel to obtain a yellow solid 0.314 g, yield 74.3%, m.p. 244-246 °C.
[0161] 1 H NMR (600 MHz, Chloroform-d) δ 9.34 (d, J = 2.1 Hz, 2H), 9.27 (t, J = 2.1 Hz, 1H), 7.65 (s, 1H), 7.29 (dd, J = 7.9, 1.6 Hz, 1H), 7.13 (dd, J = 7.4, 1.6 Hz, 1H), 6.95 (t, J = 7.6 Hz, 1H), 5.23 (s, 2H), 1.41 (s, 9H). 13 C NMR (151 MHz, Chloroform-d) δ 171.13, 167.07, 153.28, 149.19, 138.23, 130.64, 129.05, 127.86, 127.43, 126.75, 122.17, 121.98, 121.65, 118.03, 63.38, 34.61, 29.67. MS (ESI-TOF) m / z: 423.14 (M+H) + .
[0162] Example 15: Synthesis of 3-(6,8-di-tert-butyl-2H-benzopyran-3-yl)-5-(3,5- dinitrophenyl)-1,2,4-oxadiazole (W-15)
[0163]
[0164] Following the procedure of Example 3, only replacing 2-fluoro-5-nitrobenzoic acid with 3,5-dinitrobenzoic acid, a yellow powder 0.388 g was obtained, yield 81.1%, m.p. 201-204 °C.
[0165] 1H NMR (600 MHz, Chloroform-d) δ 9.34 (d, J = 2.1 Hz, 2H), 9.27 (t, J = 2.1 Hz, 1H), 7.68 (s, 1H), 7.34 (d, J = 2.4 Hz, 1H), 7.14 (d, J = 2.4 Hz, 1H), 5.20 (d, J = 1.3 Hz, 2H), 1.42 (s, 9H), 1.33 (s, 9H). 13 C NMR (151 MHz, Chloroform-d) δ 171.07, 167.17, 151.03, 149.20, 144.06, 137.43, 131.29, 127.85, 127.49, 126.34, 123.45, 121.95, 121.56, 117.80, 63.40, 34.80, 34.39, 31.46, 29.74. MS (ESI-TOF) m / z: 479.18 (M+H) + .
[0166] Example 16: Synthesis of 3-(6-chloro-2H-chromen-3-yl)-5-(3-methoxycarbonyl-5- nitrophenyl)-1,2,4-oxadiazole (W-16)
[0167]
[0168] Following the procedure of Example 4, substituting only 2-fluoro-5-nitrobenzoic acid with 3-methoxycarbonyl-5-nitrobenzoic acid, there was obtained a yellow powder, 0.285 g, in 68.6% yield, m.p. 206-208°C.
[0169] 1 H NMR (600 MHz, Chloroform-d) δ 9.34 (d, J = 2.1 Hz, 2H), 9.27 (t, J = 2.1 Hz, 1H), 7.68 (s, 1H), 7.34 (d, J = 2.4 Hz, 1H), 7.14 (d, J = 2.4 Hz, 1H), 5.20 (d, J = 1.3 Hz, 2H), 1.42 (s, 9H), 1.33 (s, 9H). 13 C NMR (151 MHz, Chloroform-d) δ 171.07, 167.17, 151.03, 149.20, 144.06, 137.43, 131.29, 127.85, 127.49, 126.34, 123.45, 121.95, 121.56, 117.80, 63.40, 34.80, 34.39, 31.46, 29.74. MS (ESI-TOF) m / z: 479.18 (M+H)+ .
[0170] Example 17: Synthesis of 3-(6,8-di-tert-butyl-2H-chromen-3-yl)-5-(3- methoxycarbonyl-5-nitrophenyl)-1,2,4-oxadiazole (W-17)
[0171]
[0172] Following the procedure of Example 3, substituting only 2-fluoro-5-nitrobenzoic acid with 3-methoxycarbonyl-5-nitrobenzoic acid, there was obtained a yellow powder, 0.445 g, 90.5% yield, m.p. 183-185 °C.
[0173] 1 H NMR (600 MHz, Chloroform-d) δ 8.91 (d, J = 2.6 Hz, 1H), 8.48 (d, J = 5.3 Hz, 1H), 8.24 (dd, J = 9.4, 2.6 Hz, 1H), 7.41 (d, J = 1.3 Hz, 1H), 7.25 (d, J = 2.4 Hz, 1H), 7.04 (d, J = 2.3 Hz, 1H), 6.75 (d, J = 9.4 Hz, 1H), 5.12 (d, J = 1.3 Hz, 2H), 3.13 (d, J = 5.0 Hz, 3H), 1.35 (s, 9H), 1.27 (s, 9H). 13 C NMR (151 MHz, Chloroform-d) δ 172.20, 166.95, 163.87, 150.98, 148.88, 143.93, 137.34, 134.14, 133.32, 130.75, 127.82, 126.64, 126.33, 126.10, 123.38, 121.67, 118.19, 63.48, 53.29, 34.79, 34.38, 31.46, 29.75. MS (ESI-TOF) m / z: 492.22 (M+H) + .
[0174] Example 18: Synthesis of 3-(6,8-di-tert-butyl-2H-chromen-3-yl)-5-(2- methylamino-5-nitrophenyl)-1,2,4-oxadiazole (W-18)
[0175]
[0176] Following the procedure of Example 3, substituting only 2-fluoro-5-nitrobenzoic acid with 2-methylamino-5-nitrobenzoic acid, there was obtained a yellow powder, 0.365 g, 78.9% yield, m.p. 244-246 °C.
[0177] 1 H NMR (600 MHz, Chloroform-d) δ 8.98 (d, J = 2.6 Hz, 1H), 8.55 (d, J = 5.3 Hz, 1H), 8.31 (dd, J = 9.4, 2.6 Hz, 1H), 7.48 (s, 1H), 7.32 (d, J = 2.4 Hz, 1H), 7.11 (d, J = 2.3 Hz, 1H), 6.82 (d, J = 9.4 Hz, 1H), 5.19 (s, 2H), 3.20 (d, J = 5.0 Hz, 3H), 1.42 (s, 9H), 1.34 (s, 9H). 13 CNMR (151 MHz, Chloroform-d) δ 172.69, 165.36, 152.32, 151.00, 143.88, 137.44, 136.82, 129.87, 129.55, 126.81, 126.07, 123.14, 121.61, 118.37, 110.57, 104.48, 63.56, 34.80, 34.39, 31.48, 30.27, 29.74. MS (ESI-TOF) m / z: 463.23 (M+H) + .
[0178] Example 19: Synthesis of 3-(6-chloro-2H-chromen-3-yl)-5-(3-nitrophenyl)-1,2,4- oxadiazole (W-19)
[0179]
[0180] Following the procedure of Example 4, substituting only 2-fluoro-5-nitrobenzoic acid for 3-nitrobenzoic acid, there was obtained a yellow powder, 0.278 g, 78.2% yield, m.p. 190-192°C.
[0181] Example 20: Synthesis of 3-(8-tert-butyl-2H-chromen-3-yl)-5-(3-methoxycarbonyl-5- dinitrophenyl)-1,2,4-oxadiazole (W-20)
[0182]
[0183] Following the procedure of Example 14, substituting only 3,5-dinitrobenzoic acid for 3-methoxycarbonyl-5-nitrobenzoic acid, there was obtained a yellow powder, 0.369 g, 84.7% yield, m.p. 218-219°C.
[0184] 1H NMR (600 MHz, Chloroform-d) δ 9.20 (t, J = 1.9 Hz, 1H), 9.14 (t, J = 1.6 Hz, 1H), 9.08 (t, J = 1.9 Hz, 1H), 7.63 (d, J = 1.4 Hz, 1H), 7.28 (dd, J = 7.9, 1.6 Hz, 1H), 7.12 (dd, J = 7.4, 1.6 Hz, 1H), 6.94 (t, J = 7.6 Hz, 1H), 5.22 (d, J = 1.2 Hz, 2H), 4.07 (s, 3H), 1.41 (s, 9H). 13 CNMR (151 MHz, Chloroform-d) δ 172.29, 166.86, 163.87, 153.24, 148.88, 138.16, 134.17, 133.33, 130.13, 128.84, 127.86, 126.68, 126.64, 126.27, 122.28, 121.57, 118.42, 63.46, 53.30, 34.60, 29.68. MS (ESI-TOF) m / z: 436.15 (M+H) + .
[0185] The compounds of the above examples are all 1 H NMR, 13 C NMR, MS to confirm the structure of the compounds. Due to the limitation of the length, the 1 H NMR, 13 C NMR, MS figures of the compound W-2 are shown in Figures 3-5 .
[0186] The structural formula of the compounds of examples 1-20 is shown in Table 1.
[0187] Table 1 Structural formula of the compounds of examples 1-20
[0188]
[0189]
[0190] Experiment 1: In vitro TLR2 / 1 agonistic activity screening
[0191] The HEK293T cell dual luciferase reporter gene model expressing hTLR2 / 1 was used to evaluate the TLR2 / 1 agonistic activity of the compounds by transient co-transfection. HEK293T cell is a commonly used tool cell, which is suitable for transfection, protein expression and other experiments. The DNA plasmids of human TLR2 and human TLR1 were introduced into HEK293T cells by transient co-transfection technology, so that they could temporarily express hTLR2 / 1. In order to detect the hTLR2 / 1 agonistic activity, the firefly luciferase (FLuc) gene plasmid for detecting the agonistic level of NF-κB and the sea cucumber luciferase (RLuc) gene plasmid as an internal reference were also introduced into HEK293T. The two fluorescent enzyme catalytic luminescence intensities were detected at different wavelengths using a kit, and the ratio RLU (fold) was used as an evaluation index of agonistic activity.
[0192] The compounds in Table 1 were prepared into 10.0 mM stock solution with DMSO, and diluted to 10 μM with DMEM(H) medium to obtain the medium solution of the compounds to be screened. The logarithmic growth phase of HEK293T cells was centrifuged at 900 r / min for 5 min, the cells were resuspended with DMEM(H) complete medium, and the cell density was adjusted to 5×10 5 / mL. 5 million cells were inoculated in a 96-well culture plate. 0.6 mL of Opti-MEM medium (purchased from Thermo Fisher Scientific) was added to a sterile 1.5 mL centrifuge tube (centrifuge tube A), 25.8 μL of ExFect transfection reagent (purchased from Nanjing Nvigan Biotech Co., Ltd.) was added, and the mixture was gently mixed with a pipette. 0.6 mL of Opti-MEM medium was added to another sterile 1.5 mL centrifuge tube (centrifuge tube B), and 6000 ng of pcDNA3.1(+)-hTLR2, 6000 ng of pcDNA3.1(+)-hTLR1, 750 ng of pNFκB-luc, and 120 ng of pRL-SV40-C plasmid (all purchased from Shanghai Biyun Tian Biotechnology Co., Ltd.) were sequentially added, and the mixture was gently mixed with a pipette. The ExFect-Opti-MEM in the centrifuge tube A was added dropwise to the diluted plasmid solution in the centrifuge tube B, and the mixture was gently mixed and placed at room temperature for 20 minutes to obtain a transfection working solution. When the cells grew to 70-80% of the bottom area of the well plate, the transfection working solution was added dropwise to the 96-well plate at 20 μL per well, and the mixture was gently mixed and placed in a 37°C, 5% CO2 incubator for culture. After 24 hours, the medium in each well was replaced with a medium solution of the compound to be screened at a final concentration of 10 μM, and three replicate wells were set up for each compound, and a blank control was set up. After 24 hours of continuous culture, the fluorescence was detected according to the instructions of the Biyun Tian Dual Luciferase Reporter Gene Detection Kit (RG027), and the ratio of the luciferase and sea cucumber luciferase catalyzed luminescence intensity RLU (fold) was used as the evaluation index of agonistic activity. The experimental results are shown in Table 2.
[0193] Table 2 Screening results of TLR2 / 1 agonistic activity of compounds in vitro
[0194]
[0195] The experimental results show that, compared with the blank group, 10 μM of W-1, W-2, W-3, W-4, W-5, W-6, W-16 and W-17 exhibit obvious TLR2 / 1 agonistic activity, and it is speculated that these compounds may play a radiation protection role by targeting TLR. The results also show that the selection of substituents on the 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivative provided by the present application has a great influence on the TLR2 / 1 agonistic activity.
[0196] The EC50 of W-1 and W-2 in agonizing TLR2 / 1 was further determined 50The experimental procedure was similar to the TLR2 / 1 agonistic activity screening process, except that the TLR2 / 1 agonistic activity of different concentrations of compounds W-1 and W-2 was determined. Compounds W-1 and W-2 were set at 100 μM, 33.3 μM, 11.1 μM, 3.7 μM, 1.23 μM, 0.45 μM, 0.15 μM, 0.05 μM, 0.015 μM, 0.005 μM, 0.0015 μM, 0.0005 μM, 0.00015 μM, 0.00005 μM, and 0 μM, with 3 replicates for each concentration, and the experiment was repeated three times independently. The ratio of the luciferase and sea anemone luciferase catalyzed luminescence intensity RLU (fold) was used as an evaluation index of the agonistic activity. The comparison of the NF-κB agonistic activity of compounds W-1 and W-2 on the hTLR2 / 1-expressing HEK293T cells constructed by transient co-transfection is shown in FIG. 1. Figure 1 The RLU (fold) values were subjected to non-linear regression analysis to calculate the EC 50 values by using the GraphPad Prism 5 software. The EC 50 value of W-1 was 30.06 ± 0.35 nM, and the EC 50 value of W-2 was 18.57 ± 0.98 nM. The results showed that the EC 50 values of compounds W-1 and W-2 were low, indicating that the TLR2 / 1 agonistic activity of compounds W-1 and W-2 was high.
[0197] Experiment 2: 30-day survival experiment of irradiated mice
[0198] The compounds in Table 1 were selected to carry out the 30-day survival experiment of irradiated mice, and the positive drug was selected as nilestriol. Adult male C57 / BL mice were bred by Beijing Sbielfo Biotechnology Co., Ltd., and the body weight of the mice was 20-22 g. The experimental animal license number was SCXK (Jing) 2019-0010. The mice were bred in a SPF laboratory, 5 mice per cage, fed with specially prepared feed for mice, and free water. The temperature in the animal laboratory was maintained at 25°C, and the relative humidity was 40%-70%, with 12 hours of daylight per day. The solvent was 20% hydroxypropyl-β-cyclodextrin (HPCD) in normal saline, and nilestriol was prepared into a 0.5 mg / mL solution with 20% HPCD in normal saline; the compounds in Table 1 were prepared into a 8 mg / mL suspension with 20% HPCD in normal saline.
[0199] The experiment included a radiation control group (administered physiological saline containing 20% HPCD), a soliestrol group (5 mg / kg), and an experimental group (80 mg / kg). The radiation control and experimental groups received intraperitoneal injections, administered twice daily (0.2 mL / animal) 24 hours and 15 minutes before irradiation. The soliestrol group received gavage, administered once daily (0.2 mL / animal) 24 hours before irradiation. The irradiation radiation was... 60 The irradiation dose of Go gamma rays was 8.5 Gy, the irradiation dose rate was 71.11 cGy / min, and the irradiation method was whole-body irradiation. The survival of mice was observed for 30 days, with the day of irradiation as day 0. The survival of mice from day 0 to day 30 was observed. The weight of mice was measured on days 1, 4, 7, 10, 14, 18, 22, and 30 after irradiation, and the weight change of mice over 30 days was recorded.
[0200] Taking compound W-2 as an example, the experimental results are shown in Table 3. Figure 2 And Table 4. From Table 3 and Figure 2 It can be seen that after whole-body irradiation with 8.5 Gy, the mice in the radiation-treated group died rapidly within 15 days; the survival rate of the mice in the positive control group (nystatin) was 50% after 30 days of irradiation, while the survival rate of the experimental W-2 group was 100%. Statistical analysis of the mouse survival curves was performed using GraphPad Prism 5 software. The differences between the W-2 group and the nystatin group and the radiation control group were statistically significant (p < 0.0001, p = 0.0115), and the difference between the W-2 group and the nystatin group was also statistically significant (p = 0.0115). Table 3 shows the changes in body weight of irradiated mice over 30 days. The body weight of the mice in the radiation-treated group continued to decrease after irradiation; the weight loss in the nystatin group continued until day 18, and the weight loss in the W-2 group continued until day 14. After that, the body weight of the mice in the nystatin group and the W-2 group began to recover, and by day 30, it had basically returned to the pre-irradiation level. On day 10 post-irradiation, mice in both the nystatin and W-2 groups had significantly higher body weights than the irradiation control group, with the W-2 group showing a significantly higher body weight. On days 18, 22, and 30 post-irradiation, the W-2 group also showed significantly higher body weights than the nystatin group. These results indicate that compound W-2 has good radioprotective effects at a dose of 80 mg / kg, effectively improving the survival rate of mice exposed to lethal doses of radiation, and its effect is superior to that of the 5 mg / kg nystatin group.
[0201] Table 3. Mouse survival experiment after 30 days
[0202] Group Number of mice Number of mice Survival rate of mice Radiation control group 10 0 0% Nylestriol group (5 mg / kg) 10 5 50% W-2 group (80 mg / kg) 10 10 100%
[0203] Table 4. Weight changes of irradiated mice over 30 days.
[0204]
[0205] Experiment three: in vitro anti-tumor activity experiment of compounds
[0206] In this experiment, the LDH method, i.e. lactic dehydrogenase (LDH) detection method, was used to detect the proliferation and growth of four common tumor cells. The four tumor cells include Hela cells (cervical cancer cells), MCF-7 cells (breast cancer cells), HepG2 (liver cancer cells) and A549 cells (non-small cell lung cancer cells).
[0207] The logarithmic growth phase MCF-7, Hela, HepG2, A549 cells were centrifuged at 900 r / min for 5 min, resuspended with DMEM(H) complete culture medium, and the cell density was diluted to 5×10 5 / mL, and 50,000 cells were inoculated into each well of a 96-well plate. After 24 h of culture, the complete culture medium containing different concentrations of compounds in Table 1 was replaced, so that the final concentration of the compound was 100 μM, 10 μM, 1 μM, 0.1 μM, 0.01 μM. The blank control group was replaced with complete culture medium without compound. After 24 h of continuous culture, the cell survival rate was detected by lactic dehydrogenase cytotoxicity detection kit (Bi Yun Tian, C0016). Specifically, the supernatant was removed, 150 μL of 10-fold diluted (with PBS) LDH release agent was added, and then it was shaken appropriately, and then it was incubated in a cell incubator for 1 hour. Then 120 μL of supernatant was taken and added to a new 96-well plate; 60 μL of LDH detection working solution was added to each well, mixed well, and then incubated at room temperature (25°C) for 30 min in the dark; then the absorbance was measured at 490 nm. Three replicate wells were set for each compound concentration, and the experiment was repeated three times independently. Cell survival rate (%) = 100% - 100% × (compound absorbance - blank control well absorbance) / (absorbance of maximum enzyme activity of cells - absorbance of blank control well), and the IC 50 value of cell survival rate was calculated by non-linear regression analysis using GraphPad Prism 5 software. For example, compound W-2, the results are shown in Table 5.
[0208] Table 5 Effect of W-2 on the in vitro proliferation of four tumor cells
[0209]
[0210] The results of Table 5 show that compound W-2 has a significant inhibitory effect on the proliferation of four tumor cells at a concentration of 10-100 μM, and the IC 50 values of the four tumor cells are in the range of 6.57-11.04 μM, and the IC 50 values are low, indicating that compound W-2 can inhibit the proliferation of four tumor cells at a lower concentration, and has the potential to be developed as a broad-spectrum anti-tumor drug.
[0211] The above merely describes the preferred embodiments of the present application, and it should be pointed out that, for those skilled in the art, several improvements and refinements can be made without departing from the principles of the present application, and these improvements and refinements should also be considered as falling within the protection scope of the present application.
Claims
1. A class of 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivatives, characterized in that, The structure is shown as formula I, R1 is selected from H, halogen, alkoxy, alkyl; R2 is selected from H, alkyl; R3 is selected from halogen, alkylamine; R4 is selected from H, nitro, alkoxycarbonyl; R5 is selected from nitro; The alkoxy is methoxy, ethoxy, propoxy, isopropoxy; The alkyl is methyl, ethyl, propyl, butyl, isobutyl or tert-butyl; The alkylamine is methylamine, ethylamine, propylamine or isopropylamine; The alkoxycarbonyl is methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl or isopropoxycarbonyl.
2. The 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivative according to claim 1, characterized in that, R3 is selected from halogen.
3. The 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivative according to claim 1, characterized by R3 is selected from F.
4. The 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivative according to claim 2 or 3, characterized in that R1 is selected from H, halogen, alkoxy, alkyl; R2 is selected from H, alkyl; R4 is selected from H.
5. The 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivative according to any one of claims 1-3, characterized in that, The alkoxy is methoxy or ethoxy; and / or The alkyl is methyl or tert-butyl; and / or The alkylamine is methylamine or ethylamine; and / or The alkoxycarbonyl is methoxycarbonyl or isopropoxycarbonyl.
6. The 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivative according to claim 4, characterized in that, The alkoxy is methoxy or ethoxy; and / or The alkyl is methyl or tert-butyl; and / or The alkylamine is methylamine or ethylamine; and / or The alkoxycarbonyl is methoxycarbonyl or isopropoxycarbonyl.
7. The 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivative according to claim 1, characterized by Any one of the following: 3-(2H-benzopyran-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4-oxadiazole; 3-(6-fluoro-2H-benzopyran-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4-oxadiazole; 3-(6,8-di-tert-butyl-2H-benzopyran-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4-oxadiazole; 3-(6-chloro-2H-benzopyran-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4-oxadiazole; 3-(6-methoxy-2H-benzopyran-3-yl)-5-(2-fluoro-5-nitrophenyl)-1,2,4-oxadiazole; 3-(6-fluoro-2H-benzopyran-3-yl)-5-(2-methylamino-5-nitrophenyl)-1,2,4-oxadiazole; 3-(6-fluoro-2H-benzopyran-3-yl)-5-(2-chloro-5-nitrophenyl)-1,2,4-oxadiazole; 3-(6-chloro-2H-benzopyran-3-yl)-5-(2-chloro-5-nitrophenyl)-1,2,4-oxadiazole; 3-(6-methoxy-2H-benzopyran-3-yl)-5-(2-chloro-5-nitrophenyl)-1,2,4-oxadiazole; 3-(6,8-di-tert-butyl-2H-benzopyran-3-yl)-5-(2-methylamino-5-nitrophenyl)-1,2,4-oxadiazole.
8. A composition comprising the 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivative of any one of claims 1 to 7, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
9. Use of the 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivative of any one of claims 1 to 7 or the composition of claim 8 for the manufacture of a medicament for the treatment and / or prevention of radiation damage.
10. Use of the 3-(2H-benzopyran-3-yl)-5-phenyl-1,2,4-oxadiazole derivative of any one of claims 1 to 7 or the composition of claim 8 for the manufacture of an antitumor medicament.
11. Use according to claim 10, characterized in that, The tumor is selected from the group consisting of cervical cancer, breast cancer, liver cancer and non-small cell lung cancer.
